Reuters
@Reuters·4.2M subscribers·86.9K videos
Breakingviews TV: AstraZeneca's big and bold deal
Posted
December 14, 2020
Views
1,534
Likes
19
Engagement
1.24%
December 14, 2020
1,534
19
1.24%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
1:24Now PlayingAstraZeneca will pay $39 billion for U.S. biotech Alexion, which makes treatment for a rare immune disease. Competition and a wayward M&A strategy have depressed the target’s stock. As Neil Unmack argues, that’s both a threat and an opportunity for the UK group’s CEO Pascal Soriot.
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on
Follow Reuters on Facebook
Follow Reuters on Twitter
Follow Reuters on Instagram
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
